Abstract
Background: The polycystic ovary syndrome (PCOS) is the commonest endocrine disorder in women of reproductive age and shows substantial phenotypic variability. According to the presence of the three diagnostic criteria of PCOS, i.e. oligo- and/or anovulation, hyperandrogenemia and/or clinical signs of high androgen levels, and polycystic ovaries, four different phenotypes of PCOS are identified. It appears that these phenotypes differ in the prevalence of several established and emerging cardiovascular risk factors. Methods: We searched the literature for studies that compared the cardiovascular risk profile of patients with the different phenotypes of PCOS. Results: Patients with both anovulation and hyperandrogenemia have more pronounced insulin resistance and higher levels of proinflammatory and prothrombotic mediators than patients with polycystic ovaries and either anovulation or hyperandrogenemia. Conclusion: Given that these differences appear to be mainly driven by the more pronounced obesity of the former patients, diet and exercise aiming at weight loss should constitute the cornerstone of management of PCOS and should be particularly emphasized in patients with the higher risk phenotypes of the syndrome.
Keywords: Polycystic ovary syndrome, phenotypes, diagnostic criteria, anovulation, hyperandrogenemia, polycystic ovaries, cardiovascular risk.
Current Pharmaceutical Design
Title:Cardiovascular Risk in the Different Phenotypes of Polycystic Ovary Syndrome
Volume: 22 Issue: 36
Author(s): Konstantinos Tziomalos
Affiliation:
Keywords: Polycystic ovary syndrome, phenotypes, diagnostic criteria, anovulation, hyperandrogenemia, polycystic ovaries, cardiovascular risk.
Abstract: Background: The polycystic ovary syndrome (PCOS) is the commonest endocrine disorder in women of reproductive age and shows substantial phenotypic variability. According to the presence of the three diagnostic criteria of PCOS, i.e. oligo- and/or anovulation, hyperandrogenemia and/or clinical signs of high androgen levels, and polycystic ovaries, four different phenotypes of PCOS are identified. It appears that these phenotypes differ in the prevalence of several established and emerging cardiovascular risk factors. Methods: We searched the literature for studies that compared the cardiovascular risk profile of patients with the different phenotypes of PCOS. Results: Patients with both anovulation and hyperandrogenemia have more pronounced insulin resistance and higher levels of proinflammatory and prothrombotic mediators than patients with polycystic ovaries and either anovulation or hyperandrogenemia. Conclusion: Given that these differences appear to be mainly driven by the more pronounced obesity of the former patients, diet and exercise aiming at weight loss should constitute the cornerstone of management of PCOS and should be particularly emphasized in patients with the higher risk phenotypes of the syndrome.
Export Options
About this article
Cite this article as:
Tziomalos Konstantinos, Cardiovascular Risk in the Different Phenotypes of Polycystic Ovary Syndrome, Current Pharmaceutical Design 2016; 22 (36) . https://dx.doi.org/10.2174/1381612822666160720162707
DOI https://dx.doi.org/10.2174/1381612822666160720162707 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Consequences of Aberrant Insulin Regulation in the Brain: Can Treating Diabetes be Effective for Alzheimers Disease
Current Neuropharmacology subject Index To Volume 1
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Marine Derived Anticancer Drugs Targeting Microtubule
Recent Patents on Anti-Cancer Drug Discovery Blockade of Chemokine-Mediated Tissue Injury in Lupus Nephritis
Endocrine, Metabolic & Immune Disorders - Drug Targets Novel Diagnostics R&D for Public Health and Personalized Medicine in Taiwan: Current State, Challenges and Opportunities
Current Pharmacogenomics and Personalized Medicine Virtual Screening, Docking, Synthesis and Bioactivity Evaluation of Thiazolidinediones as Potential PPARγ Partial Agonists for Preparation of Antidiabetic Agents
Letters in Drug Design & Discovery The Protective Effects of Pioglitazone Against Cognitive Impairment Caused by L-methionine Administration in a Rat Model
CNS & Neurological Disorders - Drug Targets Synthesis, Antidiabetic and Hypolipidemic Activities of New Diethylamine and Triethoxysilyl Derivatives of Tolbutamide on Rats
Medicinal Chemistry A Review on The Role of VEGF in Tamoxifen Resistance
Anti-Cancer Agents in Medicinal Chemistry Vitamin D and Metabolic Syndrome: Is There a Link?
Current Pharmaceutical Design RNA Interference as a Therapeutic Strategy for the Treatment of Liver Diseases
Current Pharmaceutical Design Is There a Role for Curcumin Supplementation in the Treatment of Non-Alcoholic Fatty Liver Disease? The Data Suggest Yes
Current Pharmaceutical Design The Effects and Underlying Mechanisms of Cell Therapy on Blood-Brain Barrier Integrity After Ischemic Stroke
Current Neuropharmacology Editorial [Hot Topic: Intrinsically Disordered Proteins: A Focused Look at Fuzzy Subjects (Guest Editor: Vladimir N. Uversky)]
Current Protein & Peptide Science Graphical Abstracts
Current Organic Chemistry Pregnancy and Lactation in Adolescence: Possible Implications for Calcium Metabolism and Bone Mass
Current Nutrition & Food Science Applications of Umbilical Cord Derived Mesenchymal Stem Cells in Autoimmune and Immunological Disorders: From Literature to Clinical Practice
Current Stem Cell Research & Therapy Prediction and Diagnosis of Post Transplant Diabetes
Current Diabetes Reviews Promising Potential of Dietary (Poly)Phenolic Compounds in the Prevention and Treatment of Diabetes Mellitus
Current Medicinal Chemistry Characterization of β-Sitosterol for Potential Selective GR Modulation
Protein & Peptide Letters